- Please check and comment entries here.
mitochondrially encoded tRNA leucine 1 (UUA/G)
The MT-TL1 gene provides instructions for making a molecule called a transfer RNA (tRNA), which is a chemical cousin of DNA. Transfer RNAs help assemble protein building blocks (amino acids) into functioning proteins. The MT-TL1 gene provides instructions for making a specific form of tRNA that is designated as tRNALeu(UUR). During protein assembly, this molecule attaches to the amino acid leucine (Leu) and inserts it into the appropriate locations in the growing protein.
The tRNALeu(UUR) molecule is present in cellular structures called mitochondria. These structures convert energy from food into a form that cells can use. Within mitochondria, tRNALeu(UUR) is involved in the assembly of proteins that carry out a series of chemical steps called oxidative phosphorylation. This process uses oxygen, simple sugars, and fatty acids to create adenosine triphosphate (ATP), the cell's main energy source.
In certain cells in the pancreas, called beta cells, mitochondria also play a role in controlling the amount of sugar (glucose) in the bloodstream. In response to high glucose levels, mitochondria help trigger the release of a hormone called insulin. Insulin regulates blood sugar levels by controlling how much glucose is passed from the blood into cells to be converted into energy.
2. Health Conditions Related to Genetic Changes
2.1. Maternally inherited diabetes and deafness
At least one mutation in the MT-TL1 gene causes maternally inherited diabetes and deafness (MIDD). People with this condition have diabetes and sometimes hearing loss, particularly of high tones. Less commonly, affected individuals have problems with their eyes, muscles, heart, or kidneys. The MT-TL1 gene mutation is the most common mutation in MIDD, involved in 85 percent of cases. It changes a single DNA building block (nucleotide) in the MT-TL1 gene; the nucleotide adenine is replaced by the nucleotide guanine at position 3243 in the gene (written as A3243G).
The A3243G mutation reduces the ability of tRNALeu(UUR) to add leucine to proteins that are being assembled, which slows protein production. Researchers believe that the A3243G mutation impairs the ability of mitochondria to help trigger insulin release. In people with MIDD, diabetes results when the beta cells do not produce enough insulin to regulate blood sugar effectively. Researchers have not determined how the A3243G mutation leads to hearing loss or the other features of MIDD.
2.2. Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
Several mutations in the MT-TL1 gene have been identified in people with a condition called mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). This condition is characterized by recurrent severe headaches, muscle weakness (myopathy), hearing loss, stroke-like episodes including a loss of consciousness, seizures, and other problems affecting the nervous system. Most of these mutations change single nucleotides in the gene. The A3243G mutation (described above) is the most common mutation in MELAS. It is responsible for about 80 percent of all MELAS cases. This mutation impairs the ability of mitochondria to make proteins, use oxygen, and produce energy. Researchers have not determined how changes in mtDNA lead to the specific signs and symptoms of MELAS. They continue to investigate the effects of mitochondrial gene mutations in different tissues, particularly in the brain.
2.3. Myoclonic epilepsy with ragged-red fibers
Mutations in the MT-TL1 gene have been found in a few people with features of myoclonic epilepsy with ragged-red fibers (MERRF). These individuals also have some features of MELAS (described above). This combination of signs and symptoms is called MERRF/MELAS overlap syndrome. The features of this syndrome include muscle twitches (myoclonus), muscle weakness (myopathy), difficulty coordinating movement (ataxia), hearing loss, seizures, and diabetes.
Mutations that cause MERRF/MELAS overlap syndrome each change single nucleotides in the MT-TL1 gene. Researchers have not determined how these genetic changes cause the signs and symptoms of MERRF/MELAS overlap syndrome.
2.4. Progressive external ophthalmoplegia
Mutations in the MT-TL1 gene are responsible for some cases of an eye condition called progressive external ophthalmoplegia. This disorder weakens the muscles that control eye movement and causes drooping eyelids (ptosis).
Some cases of progressive external ophthalmoplegia result from the A3243G mutation, which is the same genetic change that typically causes MELAS and MIDD (described above). It is unclear how the same MT-TL1 gene mutation can result in different conditions. Researchers have not determined how changes in mtDNA lead to the specific signs and symptoms of progressive external ophthalmoplegia, although the features of the condition may be related to impaired oxidative phosphorylation. It has been suggested that eye muscles are commonly affected by mitochondrial defects because they are especially dependent on oxidative phosphorylation for energy.
2.5. Other disorders
About 20 mutations in the MT-TL1 gene have been reported, most of which change single nucleotides in the gene. These mutations are associated with a variety of signs and symptoms chiefly affecting the muscles and nervous system. People with MT-TL1 mutations often have muscle weakness, pain, and extreme fatigue, particularly during exercise (exercise intolerance). In some cases, the heart muscle is also weakened, which is known as cardiomyopathy. This abnormality prevents the heart from pumping normally.
A few children with changes in the MT-TL1 gene have experienced delayed development, psychiatric problems, or autism spectrum disorder (which affects communication and social interaction). MT-TL1 mutations also have been identified in a small number of cases of sudden infant death syndrome (SIDS), which is a major cause of death in children younger than 1 year.
3. Other Names for This Gene
tRNA leucine 1 (UUA/G)
This entry is adapted from https://medlineplus.gov/genetics/gene/mt-tl1
- Betts J, Jaros E, Perry RH, Schaefer AM, Taylor RW, Abdel-All Z, LightowlersRN, Turnbull DM. Molecular neuropathology of MELAS: level of heteroplasmy inindividual neurones and evidence of extensive vascular involvement. NeuropatholAppl Neurobiol. 2006 Aug;32(4):359-73.
- Brackmann F, Abicht A, Ahting U, Schröder R, Trollmann R. Classical MERRFphenotype associated with mitochondrial tRNA(Leu) (m.3243A>G) mutation. Eur JPediatr. 2012 May;171(5):859-62. doi: 10.1007/s00431-011-1662-8.
- Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology ofMELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain. 1997 Oct;120 ( Pt 10):1713-21.
- Choi BO, Hwang JH, Cho EM, Jeong EH, Hyun YS, Jeon HJ, Seong KM, Cho NS, ChungKW. Mutational analysis of whole mitochondrial DNA in patients with MELAS andMERRF diseases. Exp Mol Med. 2010 Jun 30;42(6):446-55.
- Kirino Y, Goto Y, Campos Y, Arenas J, Suzuki T. Specific correlation betweenthe wobble modification deficiency in mutant tRNAs and the clinical features of ahuman mitochondrial disease. Proc Natl Acad Sci U S A. 2005 May17;102(20):7127-32.
- Liu K, Zhao H, Ji K, Yan C. MERRF/MELAS overlap syndrome due to the m.3291T>C mutation. Metab Brain Dis. 2014 Mar;29(1):139-44. doi: 10.1007/s11011-013-9464-5.
- Maassen JA, Jahangir Tafrechi RS, Janssen GM, Raap AK, Lemkes HH, 't Hart LM. New insights in the molecular pathogenesis of the maternally inherited diabetesand deafness syndrome. Endocrinol Metab Clin North Am. 2006 Jun;35(2):385-96,x-xi. Review.
- Moraes CT, Ciacci F, Bonilla E, Jansen C, Hirano M, Rao N, Lovelace RE,Rowland LP, Schon EA, DiMauro S. Two novel pathogenic mitochondrial DNA mutationsaffecting organelle number and protein synthesis. Is the tRNA(Leu(UUR)) gene anetiologic hot spot? J Clin Invest. 1993 Dec;92(6):2906-15.
- Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosisand management of maternally inherited diabetes and deafness (MIDD) associatedwith the 3243A>G mitochondrial point mutation. Diabet Med. 2008 Apr;25(4):383-99.doi: 10.1111/j.1464-5491.2008.02359.x.
- Opdal SH, Rognum TO, Torgersen H, Vege A. Mitochondrial DNA point mutationsdetected in four cases of sudden infant death syndrome. Acta Paediatr. 1999Sep;88(9):957-60.
- Palecek T, Tesarova M, Kuchynka P, Dytrych V, Elleder M, Hulkova H, Hansikova H, Honzik T, Zeman J, Linhart A. Hypertrophic cardiomyopathy due to themitochondrial DNA mutation m.3303C>T diagnosed in an adult male. Int Heart J.2012;53(6):383-7.
- Sotiriou E, Coku J, Tanji K, Huang HB, Hirano M, DiMauro S. The m.3244G>Amutation in mtDNA is another cause of progressive external ophthalmoplegia.Neuromuscul Disord. 2009 Apr;19(4):297-9. doi: 10.1016/j.nmd.2009.01.014.
- Yarham JW, Blakely EL, Alston CL, Roberts ME, Ealing J, Pal P, Turnbull DM,McFarland R, Taylor RW. The m.3291T>C mt-tRNA(Leu(UUR)) mutation is definitelypathogenic and causes multisystem mitochondrial disease. J Neurol Sci. 2013 Feb15;325(1-2):165-9. doi: 10.1016/j.jns.2012.12.003.
- Yu Wai Man CY, Chinnery PF, Griffiths PG. Extraocular muscles havefundamentally distinct properties that make them selectively vulnerable tocertain disorders. Neuromuscul Disord. 2005 Jan;15(1):17-23.Review.